Briacell, Receptor.AI to work on kinase inhibitors

Executive Summary

• Briacell Therapeutics Corp.'s subsidiary, BriaPro Therapeutics Corp., has entered into a research collaboration with Receptor.AI to develop AI-driven, isoform-selective small-molecule kinase inhibitors for cancer treatment.
• The partnership aims to expand BriaPro’s small-molecule pipeline by integrating Receptor.AI’s AI molecular design expertise with BriaPro’s proprietary technology to accelerate the discovery of selective kinase inhibitors.
• This strategic move marks Briacell's expansion beyond its core cell-based immunotherapy focus into small-molecule drug discovery, targeting improved immune-mediated tumor targeting and patient outcomes.

Key Details

• Parties Involved: Briacell Therapeutics Corp. (via subsidiary BriaPro Therapeutics Corp.) and Receptor.AI.
• Collaboration Scope: Design and development of anti-cancer isoform-selective kinase inhibitors for multiple cancer indications.
• Technology Integration: Receptor.AI will utilize its multiplatform AI-enabled drug discovery ecosystem (integrating small-molecule, peptide, and induced-proximity technologies) to drive target assessment, hit identification, and lead optimization.
• Strategic Focus: Achieving precise isoform selectivity among closely related kinases and applying rigorous ADMET (absorption, distribution, metabolism, excretion, and toxicity) constraints to enhance precision and translational confidence.
• Strategic Shift: The collaboration represents a strategic expansion for Briacell/BriaPro from cell-based immunotherapy into small-molecule discovery.

Notable Quotes

• Dr. William V. Williams, President and CEO of Briacell and BriaPro: "This partnership marks an important step in Briacell's strategic expansion beyond cell-based immunotherapy into small-molecule discovery, reinforcing its mission to deliver differentiated and complementary approaches to cancer treatment."
• Dr. Alan Nafiev, CEO and Founder of Receptor.AI: "Kinase selectivity, down to the isoform level, remains one of the hardest optimization problems in oncology. This collaboration is about bringing disciplined, AI-first molecular design and rigorous ADMET [chemical absorption, distribution, metabolism, excretion and toxicity] constraints to Briacell's oncology programs, enhancing precision and translational confidence from the earliest stages of discovery."